Seeking Alpha
11 Aug 2026, 06:15 UTC · 2h ago
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
11 Aug 2026, 06:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Protara Therapeutics' risk-adjusted fair value is estimated at $9.96 per share compared to its current price of approximately $4. — A projected valuation increase of over 100% represents a significant potential catalyst for stock price appreciation.
+0.80The IV Choline Chloride candidate targets severe choline deficiency and could generate substantial revenue upon approval. — The potential for a new, high-revenue stream increases the company's long-term fundamental value.
+0.60Pivotal data for IV Choline Chloride is not expected until 2026. — The long timeline for clinical results delays the realization of revenue and introduces extended binary risk.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
TARA-002 faces a competitive landscape and lower complete response (CR) rates in the NMIBC market. — Competitive headwinds and lower efficacy rates reduce the probability of market dominance for this specific candidate.
Which stocks this story touches
The company is rated as a 'Buy' with a fair value significantly higher than its current market price and promising drug candidates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Benzinga
14h ago
